Table 1.

Patient and tumour characteristics of men with high‐risk and locally advanced prostate cancer according to whether they were diagnosed at a hub or a spoke hospital.¹

	Hub n = 11,895		Spoke n = 15,353		All men N = 27,248
	n	%	n	%	N	%
Age group (years)
<65	2,571	21.6	3,038	19.8	5,609	20.6
65–70	2,703	22.7	3,333	21.7	6,036	22.2
70–75	2,625	22.1	3,287	21.4	5,912	21.7
>75	3,996	33.6	5,695	37.1	9,691	35.6
Ethnicity
White	10,291	92.9	13,476	93.7	23,767	93.4
Black	383	3.5	419	2.9	802	3.2
Other	399	3.6	491	3.4	890	3.5
Missing	822		967		1,789
Socioeconomic deprivation status (fifth of national distribution)
1 (least deprived)	1,651	13.9	1,858	12.1	3,509	12.9
2	1,921	16.2	2,649	17.3	4,570	16.8
3	2,386	20.1	3,273	21.3	5,659	20.8
4	2,889	24.3	3,863	25.2	6,752	24.8
5 (most deprived)	3,048	25.6	3,710	24.2	6,758	24.8
Number of co‐morbidities (RCS Charlson score)
0	8,049	75.0	10,305	71.9	18,354	73.2
1	1,911	17.8	2,805	19.6	4,716	18.8
≥2	781	7.3	1,220	8.5	2,001	8.0
Missing	1,154		1,023		2,177
T stage
1	587	5.0	837	5.5	1,424	5.3
2	2,737	23.4	3,662	24.2	6,399	23.9
3	7,873	67.3	9,918	65.6	17,791	66.4
4	507	4.3	692	4.6	1,199	4.5
Missing	191		244		435
N stage
0	9,659	87.9	12,595	87.2	22,254	87.5
1	1,329	12.1	1,846	12.8	3,175	12.5
Missing	907		912		1,819
Gleason score
6	613	7.3	1,170	10.1	1,783	8.9
7	3,900	46.1	5,143	44.3	9,043	45.0
≥8	3,944	46.6	5,306	45.7	9,250	46.1
Missing	3,438		3,734		7,172
Serum PSA (ng/mL)
<10	2,756	30.7	3,767	29.3	6,523	29.9
10–20	2,249	25.0	3,094	24.1	5,343	24.5
>20	3,982	44.3	5,983	46.6	9,965	45.7
Missing	2,908		2,509		5,417

¹Hub: hospital assigned as the lead of a regional referral network. Spoke: peripheral hospitals within the regional referral network.